Clinical Trial Update: Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the combination of dasatinib and ipilimumab in patients with gastrointestinal stromal tumor or unresectable/metastatic soft tissue sa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor
• Soft Tissue Sarcoma

Drugs mentioned

• Sprycel (dasatinib)
• Yervoy (ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gastrointestinal Stromal Tumor, Stage III Soft Tissue Sarcoma | Phase 1 | Status: COMPLETED